BSE - Delayed Quote INR

Alembic Pharmaceuticals Limited (APLLTD.BO)

Compare
1,126.30 +1.65 (+0.15%)
At close: 3:29 PM GMT+5:30
Loading Chart for APLLTD.BO
DELL
  • Previous Close 1,124.65
  • Open 1,101.40
  • Bid 1,124.85 x --
  • Ask 1,126.35 x --
  • Day's Range 1,101.40 - 1,136.00
  • 52 Week Range 710.50 - 1,296.15
  • Volume 3,958
  • Avg. Volume 17,692
  • Market Cap (intraday) 221.389B
  • Beta (5Y Monthly) 0.69
  • PE Ratio (TTM) 35.14
  • EPS (TTM) 32.05
  • Earnings Date Nov 7, 2024
  • Forward Dividend & Yield 11.00 (0.98%)
  • Ex-Dividend Date Jul 15, 2024
  • 1y Target Est 548.06

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

alembicpharmaceuticals.com

14,858

Full Time Employees

March 31

Fiscal Year Ends

Recent News: APLLTD.BO

View More

Performance Overview: APLLTD.BO

Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

APLLTD.BO
49.94%
S&P BSE SENSEX
10.02%

1-Year Return

APLLTD.BO
56.79%
S&P BSE SENSEX
23.48%

3-Year Return

APLLTD.BO
48.75%
S&P BSE SENSEX
32.31%

5-Year Return

APLLTD.BO
106.15%
S&P BSE SENSEX
97.20%

Compare To: APLLTD.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: APLLTD.BO

View More

Valuation Measures

Annual
As of 11/4/2024
  • Market Cap

    221.06B

  • Enterprise Value

    224.99B

  • Trailing P/E

    35.11

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.58

  • Price/Book (mrq)

    4.59

  • Enterprise Value/Revenue

    3.64

  • Enterprise Value/EBITDA

    22.74

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.99%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    63.04B

  • Net Income Avi to Common (ttm)

    6.3B

  • Diluted EPS (ttm)

    32.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.2B

  • Total Debt/Equity (mrq)

    10.65%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: APLLTD.BO

View More

Company Insights: APLLTD.BO

Research Reports: APLLTD.BO

View More

People Also Watch